YOLFTbeta
64

Excelsior Biopharma

6496 · TWO · Healthcare / Drug Manufacturers - Specialty & Generic

22.95TWD-0.45 (-1.92%)

Price History

Full chart

Market Stats

Previous Close23.40
Open22.85
Day Range22.70 – 23.45
52-Week Range22.50 – 30.55
Volume44.51K
Market Cap1.11B
P/E (TTM)0.00
Forward P/E0.00
EPS-4.46
Dividend Yield0.00%
Beta-0.17
50-Day Avg24.33
200-Day Avg25.75

About

Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specialty medicine and public health products. In addition, it is involved in importing and exporting of active pharmaceutical ingredients, food, and cosmeceuticals; development of cosmetics; research, importing and exporting of technologies; and pharmaceutical technologies transfer. The company was formerly known as Excelsior Enterprise Co., Ltd. and changed its name to Excelsior Biopharma Inc. in June 2003. Excelsior Biopharma Inc. was founded in 1986 and is headquartered in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Joseph Chen
  • Employees0
  • HeadquartersNo. 508, Zhongxiao E. Rd., Taipei, Taiwan, 11561, Taiwan
  • Websitehttps://www.excelsiorgroup.com.tw

Leadership

  • Mr. Joseph ChenFounder, Chairman, President & GM
  • Ms. Chia-Ling ChenRepresentative Director, New Business Development Manager & Associate Manger to the President Office
  • Mr. Po-Tang ChengSenior Director General of Taiwan Business Division
  • Ms. Ya-Wen HuangDirector General of Consumer Product Business Division
  • Ms. Pi-Ching WuDirector General of Specialty Medicine Business Division
  • Mr. Ming-Tse ChenFinancial Manager & Chief Accountant

Financials

Income Statement

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.72B1.69B1.54B1.44B1.34B671.76M771.56M861.91M898.26M
Growth (%)--1.54%-8.82%-6.26%-7.29%-49.81%+14.86%+11.71%+4.22%
Cost of Revenue1.05B1.10B1.19B1.13B1.05B384.59M464.63M479.81M538.10M
Gross Profit667.79M585.73M353.58M310.11M293.35M287.17M306.93M382.10M360.17M
Gross Margin38.93%34.68%22.96%21.48%21.92%42.75%39.78%44.33%40.10%
Operating Expense342.01M303.81M268.77M263.33M294.37M312.49M381.54M460.82M534.33M
Operating Income325.78M281.92M84.82M46.78M-1.02M-25.32M-74.61M-78.73M-174.16M
Operating Margin18.99%16.69%5.51%3.24%-0.08%-3.77%-9.67%-9.13%-19.39%
EBITDA362.68M311.76M121.64M74.15M27.63M745.00K-28.39M-8.40M-92.90M
EBITDA Margin21.14%18.46%7.90%5.14%2.06%0.11%-3.68%-0.98%-10.34%
Net Income279.68M221.83M71.01M35.30M-15.65M-33.76M-91.01M-98.70M-183.17M
Net Income Margin16.30%13.13%4.61%2.45%-1.17%-5.03%-11.80%-11.45%-20.39%
R&D60.42M39.44M51.52M57.30M56.00M42.32M62.51M83.62M96.09M
R&D as % of Total Revenue3.52%2.33%3.35%3.97%4.18%6.30%8.10%9.70%10.70%
Interest Expense0376.00K1.24M2.12M4.54M4.35M6.37M8.02M7.76M
Interest Expense % of Total Revenue0.00%0.02%0.08%0.15%0.34%0.65%0.83%0.93%0.86%

Balance Sheet

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.68B1.64B1.50B1.90B1.84B1.71B1.58B1.58B1.48B
Total Liabilities339.37M270.88M244.06M617.15M608.90M507.53M472.87M586.89M679.78M
Total Equity1.34B1.37B1.25B1.28B1.23B1.21B1.10B991.45M804.23M
Cash882.95M751.11M349.40M1.14B1.10B895.28M589.92M240.08M185.34M
Total Debt---395.38M397.19M375.83M377.40M--
Net Debt----745.28M-705.57M-519.44M-212.51M-106.42M

Cash Flow

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow349.47M126.92M-169.74M520.81M55.82M5.49M-134.75M-99.80M-138.72M
Investing Cash Flow-27.88M-32.10M-36.71M26.94M-10.68M-199.24M---
Financing Cash Flow-196.67M-226.67M-195.26M243.51M-83.04M-13.73M-317.23M--
Capital Expenditure18.10M9.54M20.37M11.62M2.88M7.78M35.66M257.15M36.95M
Free Cash Flow331.23M117.38M-190.11M509.20M52.95M-2.30M-170.41M-356.95M-175.67M
Dividends Paid186.67M186.67M186.67M46.67M46.67M----
FCF to OCF94.78%92.48%112.00%97.77%94.85%-41.87%126.46%357.67%126.63%
Dividend Paid to FCF56.36%159.03%-98.19%9.16%88.14%----

Earnings

Report DateDec 31, 2014Mar 31, 2015Jun 30, 2015Dec 2, 2015Mar 2, 2016Jun 1, 2016Aug 31, 2016Nov 30, 2016Mar 1, 2017May 31, 2017Aug 30, 2017Nov 29, 2017Feb 5, 2018May 11, 2018Aug 9, 2018Nov 13, 2018Feb 27, 2019May 3, 2019Aug 12, 2019Nov 14, 2019Feb 11, 2020May 6, 2020Aug 4, 2020Nov 5, 2020Feb 2, 2021Jun 2, 2021Sep 1, 2021Dec 1, 2021Mar 2, 2022May 10, 2022Aug 31, 2022Nov 30, 2022Mar 1, 2023May 31, 2023
EPS Estimate-------------1.331.551.60-0.870.93---------------
EPS Actual0.870.830.810.840.870.490.681.491.191.351.561.641.421.360.901.231.240.340.350.320.510.270.230.180.080.06-0.06-0.27-0.06-0.22-0.27-0.22-0.02-0.52
Surprise-------------2.26%-41.94%-23.13%--60.92%-62.37%---------------
Timing------------Pre-marketAfter-hoursPre-marketPre-market-After-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hours----Pre-market----

Key Statistics & Ratios

Market Cap1.11B
Enterprise Value1.52B
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.19
Price / Book1.61
EPS-4.46
Book Value14.83
Revenue (TTM)936.92M
Gross Profit (TTM)361.23M
EBITDA-180.39M
Profit Margin-22.05%
Operating Margin-26.21%
Return on Equity-26.05%
Return on Assets-8.80%
Shares Outstanding46.47M
Shares Float15.37M
Beta-0.17
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20211×
1.00Jul 13, 2021
20201×
1.00Jul 10, 2020
20191×
4.00Jul 10, 2019
20181×
4.00Jul 10, 2018
20171×
3.00Jul 12, 2017
20161×
2.50Aug 30, 2016
20151×
2.50Jul 16, 2015